CLLS - Cellectis SA
Cellectis SA Logo

CLLS - Cellectis SA

https://www.cellectis.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Cellectis SA, a clinical-stage biotechnology company, develops immuno-oncology products based on gene-edited T cells that express chimeric antigen receptors to attack and eradicate cancer cells. The company is headquartered in Paris, France.

52W High
$3.24
52W Low
$1.10
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
3.03
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-3.90
EV/Revenue (<3 favorable)
2.95
P/S (TTM) (<3 favorable)
4.15
P/B (<3 favorable)
2.77
Ownership
Retail‑heavy
Source: Overview
Insiders (1–5% typical)
3.85%
Institutions (25–75% balanced)
18.89%
Shares Outstanding
72,325,000
Float
38,910,200
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
63,438,000
Gross Profit (TTM)
63,438,000
EPS (TTM)
-0.59
Profit Margin (>10% good)
-0.93%
Operating Margin (TTM) (higher better)
-0.53%
ROE (TTM) (>15% strong)
-0.48%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
0.91
Momentum
Bearish momentum
Value
0.1202
Previous
0.1199
Trend
Rising
Signal Cross
No cross
As of
Sep. 12, 2025